Skip to main content

Medikamentöse Therapie nichtmelanozytärer epithelialer Tumore

Current therapy of non-melanoma skin cancer

Der Hautarzt volume 62, Article number: 430 (2011) Cite this article

Zusammenfassung

Das Basalzellkarzinom, die aktinische Keratose als Carcinoma in situ und das Plattenepithelkarzinom gehören zu den nichtmelanozytären epithelialen Hauttumoren. Diese Hautkrebsformen zählen zu den häufigsten Krebsarten weltweit mit steigenden Inzidenzen. In den letzten Jahren ist das Wissen um die Pathogenese von nichtmelanozytärem Hautkrebs gestiegen, und durch die Kenntnis der pathologischen Signalkaskaden konnten neue therapeutische Möglichkeiten identifiziert werden, die bereits zur Entwicklung einer Reihe neuer Medikamente geführt haben. Mit diesem Review wird der aktuelle Erkenntnisstand zusammengefasst, wobei wir uns auf die wichtigsten Therapien beschränken.

Abstract

Basal cell carcinoma, actinic keratosis as a carcinoma in situ and squamous cell carcinoma are classified as non-melanoma epithelial skin cancers. These forms of skin cancer are thought to be the most common cancers worldwide with rising incidences. In the past years new insights into the pathogenesis of non-melanoma skin cancers have been gained. Through knowledge of the pathologic pathways, new treatment options have become available. This review summarizes the recent advantages of treatment options of non-melanoma skin cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2

Literatur

  1. Epidemiologisches Krebsregister Nordrhein Westfalen. http://www.krebsregister.nrw.de

  2. Stang A (2007) Genital and nongenital nonmelanoma skin cancer: more epidemiological studies are needed. J Invest Dermatol 127(10):2296–2299

    PubMed  Article  CAS  Google Scholar 

  3. Crowson AN (2006) Basal cell carcinoma: biology, morphology and clinical implications. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. [Research Support, Non-U.S. Gov’t Review] 19(Suppl 2):S127–S147

  4. Nusslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287(5785):795–801

    PubMed  Article  CAS  Google Scholar 

  5. Ingham PW, Placzek M (2006) Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 7(11):841–850

    PubMed  Article  CAS  Google Scholar 

  6. Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Genet 5(7):564–573

    Article  CAS  Google Scholar 

  7. Peris K, Micantonio T, Piccolo D, Fargnoli MC (2007) Dermoscopic features of actinic keratosis. JDDG 5(11):970–976

    PubMed  Article  Google Scholar 

  8. Oberyszyn TM (2008) Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 261(2):127–136

    PubMed  Article  CAS  Google Scholar 

  9. Jensen AO, Svaerke C, Farkas D et al (2010) Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 90(5):474–479

    PubMed  Article  Google Scholar 

  10. Gerlini G, Romagnoli P, Pimpinelli N (2005) Skin cancer and immunosuppression. Crit Rev Oncol Hematol 56(1):127–136

    PubMed  Article  Google Scholar 

  11. Brantsch KD, Meisner C, Schonfisch B et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9(8):713–720

    PubMed  Article  Google Scholar 

  12. Goldberg LH, Mamelak AJ (2010) Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 9(9):1125–1132

    PubMed  Google Scholar 

  13. Ulrich C, Jurgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84

    PubMed  Article  Google Scholar 

  14. Moloney F, Vestergaard M, Radojkovic B, Damian D (2010) Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol 162(5):1138–1139

    PubMed  Article  CAS  Google Scholar 

  15. Reuschenbach M, Tran T, Faulstich F et al (2011) High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 104(8):1334–1341

    PubMed  Article  CAS  Google Scholar 

  16. Marquez C, Bair SM, Smithberger E et al (2010) Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 9(7):753–758

    PubMed  Google Scholar 

  17. Pugliano-Mauro M, Goldman G (2010) Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 36(10):1544–1553

    PubMed  Article  CAS  Google Scholar 

  18. Gibson SJ, Imbertson LM, Wagner TL et al (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15(6):537–545

    PubMed  Article  CAS  Google Scholar 

  19. Lien MH, Sondak VK (2011) Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011:571734

    PubMed  Google Scholar 

  20. Geisse J, Caro I, Lindholm J et al (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722–733

    PubMed  Article  Google Scholar 

  21. Gollnick H, Barona CG, Frank RG et al (2008) Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 18(6):677–682

    PubMed  CAS  Google Scholar 

  22. Quist SR, Gollnick HP (2011) Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Exp Opin Pharmacother 12(3):451–461

    Article  CAS  Google Scholar 

  23. Daniell MD, Hill JS (1991) A history of photodynamic therapy. Aust N Z J Surg 61(5):340–348

    PubMed  Article  CAS  Google Scholar 

  24. Morton CA, Whitehurst C, McColl JH et al (2001) Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 137(3):319–324

    PubMed  CAS  Google Scholar 

  25. Serra-Guillen C, Nagore E, Hueso L et al (2011) A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol 164(2):429–433

    PubMed  Article  CAS  Google Scholar 

  26. Schlaak M, Simon JC (2010) Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid – pilot study. JDDG 8(3):174–178

    PubMed  Article  Google Scholar 

  27. Siller G, Rosen R, Freeman M et al (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Aust J Dermatol 51(2):99–105

    Article  Google Scholar 

  28. Von Hoff DD, LoRusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164–1172

    Article  Google Scholar 

  29. Rudin CM, Hann CL, Laterra J et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173–1178

    PubMed  Article  CAS  Google Scholar 

  30. Lorusso PM, Rudin CM, Reddy JC et al (2011) Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 17(8):2512–2520

    PubMed  Article  Google Scholar 

  31. Oro AE, Higgins KM, Hu Z et al (1997) Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276(5313):817–821

    PubMed  Article  CAS  Google Scholar 

  32. Elmets CA, Viner JL, Pentland AP et al (2010) Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102(24):1835–1844

    PubMed  Article  CAS  Google Scholar 

  33. Bito T, Sumita N, Ashida M et al (2011) Inhibition of epidermal growth factor receptor and PI3 K/Akt signaling suppresses cell proliferation and survival through regulation of stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011:874571

    PubMed  Google Scholar 

  34. Ridd K, Bastian BC (2010) Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. J Invest Dermatol 130(3):901–903

    PubMed  Article  CAS  Google Scholar 

  35. Fogarty GB, Conus NM, Chu J, McArthur G (2007) Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156(1):92–98

    PubMed  Article  CAS  Google Scholar 

  36. Toll A, Salgado R, Yebenes M et al (2010) Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 19(2):151–153

    PubMed  Article  Google Scholar 

  37. Schlauder SM, Calder KB, Moody P, Morgan MB (2007) HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 29(6):559–563

    PubMed  Article  Google Scholar 

  38. Cranmer LD, Engelhardt C, Morgan SS (2010) Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 15(12):1320–1328

    PubMed  Article  Google Scholar 

  39. Maubec E, Duvillard P, Laouenan C et al (2010) Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28(15_suppl, May 20 Supplement):8510

  40. Bauman JE, Eaton KD, Martins RG (2007) Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143(7):889–892

    PubMed  Article  CAS  Google Scholar 

  41. Suen JK, Bressler L, Shord SS et al (2007) Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anti Cancer Drugs 18(7):827–829

    PubMed  Article  CAS  Google Scholar 

  42. Jalili A, Pinc A, Pieczkowski F et al (2008) Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. JDDG 6(12):1066–1069

    PubMed  Article  Google Scholar 

  43. Weinberg RA (2006) The biology of cancer. Garland Science

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Affiliations

  1. Klinik für Dermatologie und Venerologie, Hauttumorzentrum Köln, Uniklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland

    M. Schlaak, W. von Bartenwerffer & C. Mauch

Authors
  1. M. Schlaak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. von Bartenwerffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Mauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Schlaak.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schlaak, M., von Bartenwerffer, W. & Mauch, C. Medikamentöse Therapie nichtmelanozytärer epithelialer Tumore. Hautarzt 62, 430 (2011). https://doi.org/10.1007/s00105-010-2044-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00105-010-2044-2

Schlüsselwörter

  • Basalzellkarzinom
  • Plattenepithelkarzinom
  • Immuntherapie
  • Gezielte Therapie
  • Epitheliale Tumore

Keywords

  • Basal cell carcinoma
  • Squamous cell carcinoma
  • Immune therapy
  • Targeted therapy
  • Epithelial tumors